(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 August 2019 (15.08.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/157332 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *C07K 16/30* (2006.01)
A61K 39/395 (2006.01) *C07K 16/46* (2006.01)
C07K 16/28 (2006.01) *C12N 5/0783* (2010.01)

(21) International Application Number:
PCT/US2019/017284

(22) International Filing Date:
08 February 2019 (08.02.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/628,178 08 February 2018 (08.02.2018) US

(71) Applicant: **DRAGONFLY THERAPEUTICS, INC.** [US/US]; 35 Gatehouse Drive, Waltham, MA 02451 (US).

(72) Inventors: **CHANG, Gregory P.**; 143 Saunders Street, Medford, MA 02155 (US). **CHEUNG, Ann F.**; 25 Morningside Lane, Lincoln, MA 01773 (US). **GRINBERG, Asya**; 37 Follen Road, Lexington, MA 02421 (US). **GUTIERREZ, Eva**; 67 Hillcrest Street, Waltham, MA 02451 (US). **HANEY, William**; 61 Lincoln Road, Wayland, MA 01778 (US). **WAGTMANN, Nicolai**; 1776 Monument Street, Concord, MA 01742 (US). **LUNDE, Bradley M.**; 7 Lucent Drive, Lebanon, NH 03766 (US). **PRINZ, Bianka**; 7 Lucent Drive, Lebanon, NH 03766 (US).

(74) Agent: **ASHRAF, Shovon** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS

FIG. 81



(57) Abstract: Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

WO 2019/157332 A1